Table 3:
Estimated association between biomarker factor scores at Week 0 and corresponding ND outcomes at Weeks 0 and 48 and Change Between Weeks 0 and 48
| Consensus Factor* at Week 0 | BOT-2 | Reverse-Scored BRIEF GEC | KABC-II MPI | TOVA D-prime |
|---|---|---|---|---|
| Week 0 ND measurements | ||||
| A | 0·52 (−0·68, 1·71) | 0·78 (−1·11, 2·66) | 0·31 (−1·18, 1·80) | −0·04 (−0·18, 0·10) |
| B | −0·65 (−1·87, 0·57) | −1·38 (−3·28, 0·52) | −2·19 (−3·67, −0·71) | −0·22 (−0·36, −0·07) |
| C | −0·10 (−1·35, 1·14) | −0·36 (−2·32, 1·60) | 0·74 (−0·80, 2·27) | −0·09 (−0·23, 0·06) |
| D | 0·40 (−0·80, 1·60) | 1·25 (−0·63, 3·13) | −0·07 (−1·57, 1·42) | −0·08 (−0·22, 0·06) |
| E | −0·47 (−1·68, 0·74) | −0·06 (−1·97, 1·85) | −0·51 (−2·01, 0·99) | −0·07 (−0·22, 0·07) |
| F | 0·31 (−1·12, 1·73) | 0·68 (−1·56, 2·92) | 1·09 (−0·69, 2·87) | 0·08 (−0·09, 0·25) |
| Week 48 ND measurements | ||||
| A | −0·36 (−1·54, 0·82) | 0·91 (−0·79, 2·61) | −0·24 (−1·96, 1·49) | 0·05 (−0·10, 0·21) |
| B | −1·07 (−2·26, 0·12) | −1·53 (−3·23, 0·18) | −3·04 (−4·73, −1·34) | −0·18 (−0·34, −0·03) |
| C | −0·11 (−1·34, 1·11) | 0·58 (−1·19, 2·35) | 0·27 (−1·52, 2·06) | −0·05 (−0·21, 0·11) |
| D | −0·32 (−1·50, 0·86) | 0·40 (−1·30, 2·11) | −0·04 (−1·77, 1·69) | 0·17 (0·02, 0·33) |
| E | −0·49 (−1·68, 0·69) | −0·75 (−2·47, 0·97) | −1·57 (−3·29, 0·16) | 0·01 (−0·15, 0·16) |
| F | −0·41 (−1·80, 0·98) | 0·00 (−2·02, 2·02) | −0·02 (−2·08, 2·04) | 0·13 (−0·05, 0·32) |
| Week 48 - Week 0 ND measurements | ||||
| A | −0.71 (−1.54, 0.12) | 0.62 (−0.82, 2.06) | −0.43 (−1.44, 0.59) | 0.08 (−0.05, 0.21) |
| B | −0.59 (−1.44, 0.26) | −0.82 (−2.28, 0.63) | −0.91 (−1.97, 0.14) | −0.04 (−0.18, 0.10) |
| C | −0.08 (−0.95, 0.79) | 0.66 (−0.83, 2.16) | −0.45 (−1.51, 0.61) | −0.02 (−0.15, 0.12) |
| D | −0.60 (−1.43, 0.24) | −0.11 (−1.55, 1.34) | 0.03 (−0.99, 1.04) | 0.20 (0.08, 0.33) |
| E | −0.19 (−1.03, 0.65) | −0.69 (−2.14, 0.76) | −1.17 (−2.18, −0.16) | 0.04 (−0.09, 0.18) |
| F | −0.60 (−1.59, 0.39) | −0.35 (−2.06, 1.35) | −0.72 (−1.94, 0.50) | 0.05 (−0.11, 0.21) |
All analyses adjusted for site, sex, age at enrollment, age at ART initiation, ART regimen at time of biomarker specimen collection (LPV/r-based, NVP-based, or other), and whether the participant switched regimens between P1060 entry and biomarker specimen collection. Analyses involving the change between weeks 0 and 48 also adjusted for values at week 0. Estimates correspond to a one standard deviation increase in the factor score.
Significant regression coefficients (95% CI does not contain 0) denoted by grey highlighting.
Only ND measures with statistically significant relationships with the biomarker factors are shown.
KABC-II MPI = Kaufman Assessment Battery for Children, 2nd edition, Mental Processing Index; TOVA D-prime = Tests of Variables of Attention D-prime; BOT-2 = Bruininks-Oseretsky Test of Motor Proficiency, 2nd edition, Total Motor Composite Score